Data highlight strong analytical and clinical performance of Biocept's proprietary technologies, including circulating tumor DNA (ctDNA) assays, circulating tumor cell (CTC) capture, and molecular testing kits SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Biocept, Inc .
Biocept, Inc. announces availability of its new breast cancer test, OncoCEE-BR™ utilizing circulating tumor cells (CTCs) Capture, detection and enumeration Determination of HER2/neu status Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the
SAN DIEGO, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering
Biocept, Inc. announces new CFO Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr. Kachioff will be responsible for management of the company’s accounting, finance, treasury, investor relations, risk
Biocept, Inc. Announces New Director Appointment Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today the appointment of Bruce E. Gerhardt as Director. “We are pleased to welcome Bruce to our Board. His experience will be invaluable to us as we move into our next stage of
Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately?held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells in cancer patients, announced
SAN DIEGO , April 29, 2016 /PRNewswire/ -- Biocept, Inc. (" Biocept ") (Nasdaq: BIOC) today announced that it has priced a registered public offering of an aggregate of approximately 5.0 million shares of common stock at a price to the public of $1.00 per share.
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share.
Biocept, Inc. Announces Two New Director Appointments Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today the appointment of Daniel H. Petree and M. Faye Wilson as Directors. “We are pleased to welcome Dan and Faye to our Board.
